Printer Friendly

ENDOTRONICS, INC. SIGNS AGREEMENT WITH GOODWIN INSTITUTE FOR CANCER RESEARCH INC. TO EXPAND CONTRACT PRODUCTION SERVICES

    ENDOTRONICS, INC. SIGNS AGREEMENT WITH GOODWIN INSTITUTE FOR CANCER
          RESEARCH INC. TO EXPAND CONTRACT PRODUCTION SERVICES
    MINNEAPOLIS, Nov. 14 /PRNewswire/ -- Endotronics, Inc. (NASDAQ: ENDO) announced that it has signed a marketing and production agreement with Goodwin Institute for Cancer Research Inc. (GICR) to expand its cGMP production services to provide contract production for therapeutic products.
    Endotronics currently offers cGMP production services for diagnostic and research products.  The GICR will provide to Endotronics' customers therapeutic contract production services utilizing Endotronics' ACUSYST(R) technology and will comply with the Food and Drug Administration's current Good Manufacturing Practice guidelines.
    "This agreement enables Endotronics to offer both therapeutic and diagnostic contract production services to our customer base, and more importantly, provides access to our ACUSYST technology through Goodwin Institute for Cancer Research to all the companies producing products from mammalian cells," said Richard E. Sakowicz, president of Endotronics.  "This is one more step toward Endotronics becoming a full- service supplier to the bioprocessing industry."
    The Goodwin Institute for Cancer Research, based in Plantation, Fla., conducts basic experimental research and offers biotechnology services in the areas of immunology, tumor biology and virology.
    Endotronics, Inc., headquartered in Minneapolis, is a recognized industry leader in hollow fiber cell culture instrumentation.  The company's products and services are used by biotechnology, pharmaceutical, diagnostic companies and research centers worldwide for production of mammalian cell-derived human health-care products.
    -0-                         11/14/91
    /CONTACT:  Yvonne L. Marschner-Bova of Endotronics, 313-871-7350/
    (ENDO) CO:  Endotronics, Inc.; Goodwin Institute for Cancer Research Inc. ST:  Minnesota, Florida IN:  MTC SU:  CON SB -- DE011 -- 4356 11/14/91 10:57 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 14, 1991
Words:264
Previous Article:UNIMED REPORTS RECORD SALES OF MARINOL IN FISCAL YEAR RESULTS
Next Article:AMERICAN REALTY TRUST REPORTS SECOND-QUARTER RESULTS
Topics:


Related Articles
ENDOTRONICS, INC. INTRODUCES ACUMOUSE CELL CULTURE INSTRUMENT -- COST-EFFECTIVE SUBSTITUTE FOR LABORATORY MICE
ENDOTRONICS DISCONTINUES DISTRIBUTION AGREEMENT WITH VENTREX LABORATORIES -- SIGNS LETTER OF INTENT WITH NORTHUMBRIA BIOLOGICALS
ENDOTRONICS HOLDS ANNUAL MEETING OF SHAREHOLDERS: UPDATES INVESTMENT COMMUNITY ON ACUMOUSE AND ARTIFICIAL LIVER PROGRAM
ENDOTRONICS SIGNS PRODUCTION AND MARKETING AGREEMENT WITH HELIXYS
ENDOTRONICS, INC. AND WHEATON SCIENCE PRODUCTS, INC. ANNOUNCE MARKETING AND DISTRIBUTION AGREEMENT
ENDOTRONICS, INC. SIGNS STRATEGIC COOPERATION AGREEMENT WITH TECNOMARA AG OF SWITZERLAND
ENDOTRONICS REPORTS FOURTH-QUARTER AND FISCAL 1992 YEAR-END RESULTS
ENDOTRONICS, INC. UPGRADES PRODUCTION FACILITY AND SIGNS CYTOGEN CORPORATION CONTRACT
ENDOTRONICS REPORTS RESULTS FOR ITS FIRST QUARTER ENDED DEC. 31, 1992
ENDOTRONICS, INC. COMMENCES ITS SECONDARY OFFERING; CHANGES NAME TO CELLEX BIOSCIENCES

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters